Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder

Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory astrocytopathy. Rituximab for B-cell suppression is a common treatment for NMOSD; however, large-scale randomised controlled trials are lacking. Objective Evaluate long-term efficacy and safety of ritu...

全面介紹

書目詳細資料

發表在:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Main Authors:	Michael T G Hayes, Robert J Adam, Pamela A McCombe, Michael Walsh, Stefan Blum
格式:	Article
語言:	英语
出版:	SAGE Publishing 2024-04-01
在線閱讀:	https://doi.org/10.1177/20552173241257876